Assenagon Asset Management S.A. Acquires Shares of 96,629 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Assenagon Asset Management S.A. acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 96,629 shares of the biopharmaceutical company’s stock, valued at approximately $2,343,000. Assenagon Asset Management S.A. owned approximately 0.08% of Catalyst Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $27,000. Park Square Financial Group LLC purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $29,000. Farther Finance Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares in the last quarter. GAMMA Investing LLC lifted its stake in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 579 shares in the last quarter. Finally, Quarry LP purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $104,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Stephens reissued an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Robert W. Baird increased their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $32.83.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the sale, the insider now owns 42,681 shares in the company, valued at $1,127,205.21. The trade was a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,630,912.64. This represents a 74.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 247,924 shares of company stock worth $5,879,369 over the last 90 days. Insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $23.67 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.75 and a twelve month high of $26.58. The firm’s 50 day moving average price is $23.90 and its 200 day moving average price is $22.88. The firm has a market cap of $2.89 billion, a PE ratio of 20.06, a PEG ratio of 3.31 and a beta of 0.72.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.